High expectations for ustekinumab in SLE after positive Phase 2 trial

Positive results for ustekinumab in systemic lupus erythromatosus have been shown in a small Phase 2 trial of the anti-interleukin 12/23 antibody as add-on treatment. In a randomised controlled trial in 102 patients with active SLE, ustekinumab (Stelara) proved to be significantly better than placebo in improving clinical parameters of the disease. Published in the ...

Already a member?

Login to keep reading.

© 2021 the limbic